Jeremy Sohn

Jeremy joined Novartis in 2015 as VP, Head of Digital Business Development & Licensing reporting to our Chief Digital Officer and supporting Novartis’ global digital innovation programs. While serving in this role, Jeremy has also served as ad-interim Global Head of Commercial Digital Medicines (2017), overseeing the digital brand leads within the global franchises, and, Global Head of Digital Development (2016), leading Novartis’ clinical trial innovation efforts within Global Drug Development. As Head of Digital BD&L, Jeremy oversees three teams: (1) a digital health investment team (operating as dRx Capital), (2) a digital BD&L transactions team, and (3) the Novartis Biome, an internal accelerator supporting innovation partnerships across the globe.

At Novartis, Jeremy has led and/or supported multiple, first-in-pharma initiatives, including: in-licensing the first prescription digital therapeutic, investment in the first decentralized clinical trial company, designing Novartis’ intelligent salesforce optimization platform, implementing Novartis’ next-generation AI / ML strategy, and driving patient centricity and clinical trial optimization.

Prior to Novartis, Jeremy has been a serial software entrepreneur and investor with more than 20 years of experience founding, managing, and investing in healthcare and technology companies. Jeremy was Managing Director at MPM Capital where he founded and invested in two companies, CentrosHealth (acquired by Clinical Ink) and TriNetX. In 2011, Jeremy co-founded GrapeVine, a social networking company that optimizes how organizations connect with their target communities. From 2007-2011, Jeremy was COO and VP, Strategy & Corporate Development for North Plains Systems, where he lead the company's growth and eventual sale to Accel-KKR. In 2000, he co-founded an open-source operating system company, Wasabi Systems.